TELA BIO INC (TELA) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:TELA • US8723811084

0.8108 USD
+0.01 (+1.35%)
Last: Feb 6, 2026, 08:08 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

TELA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 186 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of TELA have multiple concerns. While showing a medium growth rate, TELA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • TELA had negative earnings in the past year.
  • TELA had a negative operating cash flow in the past year.
  • In the past 5 years TELA always reported negative net income.
  • TELA had a negative operating cash flow in each of the past 5 years.
TELA Yearly Net Income VS EBIT VS OCF VS FCFTELA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

  • TELA's Return On Assets of -63.32% is on the low side compared to the rest of the industry. TELA is outperformed by 69.89% of its industry peers.
  • Looking at the Return On Equity, with a value of -2504.69%, TELA is doing worse than 86.56% of the companies in the same industry.
Industry RankSector Rank
ROA -63.32%
ROE -2504.69%
ROIC N/A
ROA(3y)-56.26%
ROA(5y)-51.06%
ROE(3y)-229.9%
ROE(5y)-182.8%
ROIC(3y)N/A
ROIC(5y)N/A
TELA Yearly ROA, ROE, ROICTELA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

  • With a decent Gross Margin value of 67.23%, TELA is doing good in the industry, outperforming 72.58% of the companies in the same industry.
  • TELA's Gross Margin has improved in the last couple of years.
  • TELA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.23%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.66%
GM growth 5Y2.26%
TELA Yearly Profit, Operating, Gross MarginsTELA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • TELA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for TELA has been increased compared to 1 year ago.
  • The number of shares outstanding for TELA has been increased compared to 5 years ago.
  • Compared to 1 year ago, TELA has an improved debt to assets ratio.
TELA Yearly Shares OutstandingTELA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
TELA Yearly Total Debt VS Total AssetsTELA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • TELA has an Altman-Z score of -8.37. This is a bad value and indicates that TELA is not financially healthy and even has some risk of bankruptcy.
  • TELA's Altman-Z score of -8.37 is on the low side compared to the rest of the industry. TELA is outperformed by 74.19% of its industry peers.
  • A Debt/Equity ratio of 26.65 is on the high side and indicates that TELA has dependencies on debt financing.
  • TELA's Debt to Equity ratio of 26.65 is on the low side compared to the rest of the industry. TELA is outperformed by 87.63% of its industry peers.
Industry RankSector Rank
Debt/Equity 26.65
Debt/FCF N/A
Altman-Z -8.37
ROIC/WACCN/A
WACC11.38%
TELA Yearly LT Debt VS Equity VS FCFTELA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

  • A Current Ratio of 3.30 indicates that TELA has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 3.30, TELA is doing good in the industry, outperforming 60.22% of the companies in the same industry.
  • A Quick Ratio of 2.62 indicates that TELA has no problem at all paying its short term obligations.
  • TELA has a better Quick ratio (2.62) than 61.83% of its industry peers.
Industry RankSector Rank
Current Ratio 3.3
Quick Ratio 2.62
TELA Yearly Current Assets VS Current LiabilitesTELA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • TELA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 47.34%, which is quite impressive.
  • The Revenue has grown by 12.24% in the past year. This is quite good.
  • The Revenue has been growing by 35.01% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)47.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.76%
Revenue 1Y (TTM)12.24%
Revenue growth 3Y32.99%
Revenue growth 5Y35.01%
Sales Q2Q%9.14%

3.2 Future

  • TELA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.21% yearly.
  • TELA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.05% yearly.
EPS Next Y38.59%
EPS Next 2Y25.29%
EPS Next 3Y19.66%
EPS Next 5Y18.21%
Revenue Next Year7.66%
Revenue Next 2Y11.37%
Revenue Next 3Y13.04%
Revenue Next 5Y14.05%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
TELA Yearly Revenue VS EstimatesTELA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 20M 40M 60M 80M 100M
TELA Yearly EPS VS EstimatesTELA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5 -2 -2.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TELA. In the last year negative earnings were reported.
  • Also next year TELA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TELA Price Earnings VS Forward Price EarningsTELA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TELA Per share dataTELA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as TELA's earnings are expected to grow with 19.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.29%
EPS Next 3Y19.66%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for TELA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TELA BIO INC

NASDAQ:TELA (2/6/2026, 8:08:09 PM)

0.8108

+0.01 (+1.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-13
Earnings (Next)03-18
Inst Owners71.18%
Inst Owner Change5.96%
Ins Owners8.47%
Ins Owner Change0.42%
Market Cap35.49M
Revenue(TTM)77.06M
Net Income(TTM)-39.00M
Analysts81.82
Price Target3.52 (334.14%)
Short Float %1.19%
Short Ratio3.84
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.8%
Min EPS beat(2)-21.99%
Max EPS beat(2)6.39%
EPS beat(4)1
Avg EPS beat(4)-10.53%
Min EPS beat(4)-25.31%
Max EPS beat(4)6.39%
EPS beat(8)2
Avg EPS beat(8)-1.79%
EPS beat(12)5
Avg EPS beat(12)0.63%
EPS beat(16)5
Avg EPS beat(16)-3.48%
Revenue beat(2)0
Avg Revenue beat(2)-5.58%
Min Revenue beat(2)-6.91%
Max Revenue beat(2)-4.25%
Revenue beat(4)1
Avg Revenue beat(4)-7.97%
Min Revenue beat(4)-25.31%
Max Revenue beat(4)4.59%
Revenue beat(8)2
Avg Revenue beat(8)-5.8%
Revenue beat(12)2
Avg Revenue beat(12)-6.09%
Revenue beat(16)6
Avg Revenue beat(16)-4.2%
PT rev (1m)0%
PT rev (3m)-36.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-12.02%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.94%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-15.59%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.82%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.46
P/FCF N/A
P/OCF N/A
P/B 22.79
P/tB 344.55
EV/EBITDA N/A
EPS(TTM)-0.89
EYN/A
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.71
OCFYN/A
SpS1.76
BVpS0.04
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -63.32%
ROE -2504.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.23%
FCFM N/A
ROA(3y)-56.26%
ROA(5y)-51.06%
ROE(3y)-229.9%
ROE(5y)-182.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.66%
GM growth 5Y2.26%
F-Score4
Asset Turnover1.25
Health
Industry RankSector Rank
Debt/Equity 26.65
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 58.56%
Cap/Sales 0.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.3
Quick Ratio 2.62
Altman-Z -8.37
F-Score4
WACC11.38%
ROIC/WACCN/A
Cap/Depr(3y)110.61%
Cap/Depr(5y)96.68%
Cap/Sales(3y)2.33%
Cap/Sales(5y)2.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.76%
EPS Next Y38.59%
EPS Next 2Y25.29%
EPS Next 3Y19.66%
EPS Next 5Y18.21%
Revenue 1Y (TTM)12.24%
Revenue growth 3Y32.99%
Revenue growth 5Y35.01%
Sales Q2Q%9.14%
Revenue Next Year7.66%
Revenue Next 2Y11.37%
Revenue Next 3Y13.04%
Revenue Next 5Y14.05%
EBIT growth 1Y23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.1%
EBIT Next 3Y17.88%
EBIT Next 5Y23.27%
FCF growth 1Y25.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.14%
OCF growth 3YN/A
OCF growth 5YN/A

TELA BIO INC / TELA FAQ

Can you provide the ChartMill fundamental rating for TELA BIO INC?

ChartMill assigns a fundamental rating of 2 / 10 to TELA.


Can you provide the valuation status for TELA BIO INC?

ChartMill assigns a valuation rating of 0 / 10 to TELA BIO INC (TELA). This can be considered as Overvalued.


Can you provide the profitability details for TELA BIO INC?

TELA BIO INC (TELA) has a profitability rating of 1 / 10.


What is the financial health of TELA BIO INC (TELA) stock?

The financial health rating of TELA BIO INC (TELA) is 3 / 10.


What is the earnings growth outlook for TELA BIO INC?

The Earnings per Share (EPS) of TELA BIO INC (TELA) is expected to grow by 38.59% in the next year.